Jazz Pharmaceuticals Plc

Jazz helps people with rare sleep disorders and certain cancers manage daily symptoms. Its medicines support patients with narcolepsy, epilepsy, and aggressive cancers. These treatments aim to improve quality of life for those with few other options.

Jazz’s Medicine Cabinet: What’s Inside?

• Neuroscience (72% of sales): Medicines for narcolepsy, idiopathic hypersomnia, and epilepsy, helping patients manage sleepiness and seizures.
• Oncology (28% of sales): Treatments for blood cancers and solid tumors, including acute leukemia and small cell lung cancer.
• Oxybate Therapies (45% of sales): Xywav and Xyrem help control sudden muscle weakness and daytime sleepiness in narcolepsy.
• Cannabidiol Therapy (26% of sales): Epidiolex treats seizures in rare childhood epilepsy syndromes.
• Specialty Cancer Drugs (18% of sales): Rylaze and Zepzelca together accounted for 18% of product sales in 2025.

Growth Spurts and Strategic Moves

• Acquired GW Pharmaceuticals in 2021, adding Epidiolex to its portfolio.
• Bought Chimerix in April 2025, gaining Modeyso for brain cancer.
• Launched Modeyso (August 2025) and Ziihera (December 2024) in new cancer markets.
• Sold Sativex to CNX Therapeutics in October 2025, focusing on core areas.
• Expanded global reach through licensing deals with Zymeworks, Werewolf, and Saniona.

What Makes Jazz Stand Out in the Crowd?

Jazz focuses on rare diseases, allowing targeted sales and efficient product launches. Its global distribution uses specialty pharmacies and direct sales in key markets. The company invests heavily in research, supporting a steady pipeline of new treatments.

Five Things You Need to Know

• Revenue was $1.13 billion in Q3 2025, up 6.7% year-on-year.
• Operating income reached $251 million in Q3 2025, up 16.9% year-on-year.
• Net income dropped to $58 million in Q3 2025, down 77.9% year-on-year.
• Cash flow from operations was $475 million in Q3 2025, up 19.0% year-on-year.

Bottom Line

Jazz has evolved through acquisitions and new product launches, balancing neuroscience and cancer treatments. Its focus on rare diseases and steady R&D investment support ongoing adaptation in a competitive market.